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AbstrAct
Anaplastic astrocytoma without 1p/19q codeletion is a 
rare primary central nervous system tumour occurring 
primarily in middle-aged adults and associated with a 
median survival of 5–10 years. The major corner stone 
of treatment is maximal safe neurosurgical resection, 
followed by radiotherapy and chemotherapy. Several 
clinical trials addressed the optimal adjuvant treatment; 
however, interpretation has been challenged by the 
recent molecular marker-based reclassification of tumour. 
The interim study of the CATNON trial strongly suggests 
the addition of 12 adjuvant cycles of temozolomide in 
addition to radiotherapy after maximal safe resection 
in patients with anaplastic astrocytoma without 1p/19q 
codeletion. Based on more recently presented data from 
the second interim analysis of the CATNON trial and from 
the molecular analysis, benefit from temozolomide during 
and after radiotherapy is limited to patients with isocitrate 
dehydrogenase-mutated anaplastic astrocytoma. Given 
the small patient number in the single subgroups and 
the so far missing neurocognitive and quality of life data, 
more mature analyses needs to be awaited to draw final 
conclusions on the application of concurrent temozolomide 
treatment for the daily routine in patients who already are 
scheduled for adjuvant temozolomide. Further molecular 
analysis is ongoing to define personalised treatment 
approaches in patients with anaplastic astrocytoma.
IntroduCtIon
Lower grade astrocytomas are rare primary 
malignant intracranial tumours with only 0.41 
cases per 100 000.1 Histologically, anaplastic 
astrocytoma do not fulfil the criteria of glio-
blastoma (the presence of neoangiogenesis or 
necrosis) but show more malignant features 
compared with their low grade counterparts 
(higher cellularity, mitosis and nuclear poly-
morphism). The recent addition of molec-
ular markers to the 2016 WHO glioma clas-
sification further distinguishes between 
anaplastic astrocytomas isocitrate dehydroge-
nase (IDH) mutant (mt) and IDH wild type 
(wt).2 Anaplastic astrocytoma IDHmt are 
tumours with the presence of IDH1 codon 
132 or IDH2 codon 172 missense muta-
tions (IDHmut) and nuclear ATRX loss but 
without 1p/19q codeletion. IDHwt status in 
both low grade and anaplastic astrocytoma is 
associated with an aggressive clinical course, 
despite the similar histological appearance 
underscoring the high clinical importance 
of the IDH-based molecular classification. 
The IDHwt subgroup of anaplastic astrocy-
toma is, however, no single entity and these 
tumours require further molecular analysis. 
Many show on further analysis ‘molecular 
features of glioblastoma’ including mutations 
of the TERT promoter, EGFR amplification 
as well as combined loss of heterozygosity 
of chromosome 10q and trisomy of chromo-
some 7.3–6 Patients with these histologically 
low grade tumours have a poor outcome, and 
immediate further treatment similar to glio-
blastoma should be considered, including 
combined chemoirradiation with temozolo-
mide.
The first cornerstone in the treatment 
of anaplastic astrocytoma without 1p/19q 
codeletion—irrespective of the presence 
of an IDH mutation— - is a maximal safe 
resection.7 The significant value of complete 
resection in IDHmt astrocytoma has been 
supported by retrospective studies that 
suggest even minor tumour remnants can 
adversely affect survival.8 9 Indeed, in case 
of incomplete resected IDHmt (anaplastic) 
astrocytoma, a second look surgery should be 
considered to achieve gross total resection, if 
that is considered safe and feasible.
Clinical trials on the adjuvant treatment of 
anaplastic astrocytoma
The interpretation of past and ongoing clin-
ical trials on the optimal adjuvant treatment 
of anaplastic astrocytoma is complicated 
by the recent introduction of the molecu-
lar-based classification of glial malignancies, 
most relevant clinical trials were conducted 
or designed before introduction of the 2016 
WHO classification of central nervous system 
(CNS) tumours in 2016.2 Within several trials 
though posthoc or preplanned analysis of 
molecular characteristics were performed to 
address the efficacy of adjuvant treatment in 
the molecularly defined subgroups allowing 
recommendations for treatment in patients 
diagnosed today.
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Figure 1 2×2 study design of the CATNON trial.
The PCV chemotherapeutic schema consisting of 
procarbazine, lomustine and vincristine was investigated 
in the RTOG 9402 and EORTC 26951 trials, both originally 
designed to address adjuvant treatment in oligodendrog-
lial tumours.10 11 However, both trials included patients 
with tumours lacking 1p/19q codeletion and which thus 
represent anaplastic astrocytoma according to the 2016 
WHO classification of CNS tumours. In neither trial, the 
addition of PCV to adjuvant radiotherapy resulted in a 
statistically significant overall survival (OS) benefit in 
the 1p/19q intact tumours, but both showed trends for 
a benefit of additional PCV therapy in that particular 
population (HR RTOG study 0.85, 95% CI 0.58 to 1.23, 
p=0.39; EORTC study 0.83; 95% CI 0.62 to 1.10, p=0.18). 
Of note, the PCV regimen is associated with a rather chal-
lenging toxicity profile. In the EORTC 26951 study, about 
two-thirds of patients did not receive the fifth or sixth of 
the planned six cycles of therapy, and in 40% of patients 
early discontinuation occurred because of toxicity.12
Temozolomide, an alkylating oral chemotherapeutic 
agent, has a much better toxicity profile and is part of 
the standard combined radiochemotherapy approach in 
glioblastoma.7 The NOA-04 trial aimed to compare the 
clinical efficacy of radiotherapy to chemotherapy (either 
PCV or temozolomide) in anaplastic glioma. No statis-
tical significant difference in the efficacy between chemo-
therapy alone versus radiotherapy alone was observed. 
The results suggest that the efficacy of temozolomide is 
similar to that of the PVC regimen in patients without 
1p/19q codeletion.13 The CATNON trial (EORTC 
26053–22054) was the first study on anaplastic glioma 
to include patients based on molecular characteristics 
as study inclusion required the presence of a anaplastic 
glioma without a 1p/19q codeletion.14 In a 2×2 factorial 
design, the clinical efficacy of concomitant and adjuvant 
chemotherapy with temozolomide added to radiotherapy 
was investigated (figure 1). Importantly, the first reported 
results represent a predefined interim analysis, while 
follow-up is still immature with 70% of patients still alive 
and only 46% having experienced disease progression. 
At the time of the interim analysis, OS was substantially 
longer in patients assigned to adjuvant temozolomide 
(median OS: not reached vs 41.1 months; HR 0.67, 
95% CI 0.51 to 0.88; 5-year survival increase from 44% to 
56%).14 At the Annual Meeting of the American Society 
of Clinical Oncology 2019, the second interim analysis 
of the CATNON trial focusing of the clinical efficacy of 
concurrent temozolomide treatment was presented. In 
the entire study population, the addition of temozolo-
mide during radiotherapy did not result in a statistically 
significant improvement of the OS.15 The numerically 
the 5-year OS rate in patients with concurrent treatment 
was 53% compared with 50% in patients without concur-
rent treatment. However, results were clearly different in 
patients with IDH-mutated tumours (see below).
Predictive molecular biomarkers
In the large randomised studies, molecular studies have 
been performed to investigate the predictive impact of 
IDH and MGMT promoter methylation on outcome to 
chemotherapy.13In the NOA-04 study, in IDHwt subpop-
ulation MGMT promoter methylation was found to be a 
predictive marker for response towards temozolomide, 
while no predictive value for MGMT promoter methyl-
ation was evident in IDHmt anaplastic glioma.16 This is 
explained by the frequent methylation of the MGMT 
promoter in IDHmt tumours. Accordingly, in the RTOG 
study, IDHmt appeared to be predictive of benefit to 
PCV chemotherapy, but the similar EORTC study still 
suggested a major role for MGMT promoter methyla-
tion.10 17
In the second interim analysis of the CATNON trial, 
also the results of the molecular analysis were presented. 
As expected IDH mutational status as well as MGMT 
methylation status were prognostically highly relevant 
biomarkers. In terms of prediction of benefit to concur-
rent temozolomide during as well as adjuvant temozolo-
mide after radiotherapy, the clinical benefit was present in 
patients with an IDH mutation or MGMT promoter meth-
ylation. In patients with IDHmt tumours already receiving 
adjuvant temozolomide, a small additional benefit seems 
present if temozolomide is also given during radio-
therapy but this difference was statistically not significant. 
In numbers, patients with IDHmt anaplastic astrocytoma 
treated with concurrent as well as adjuvant temozolomide 
presented with a 5-year OS rate of 84.4% compared with 
80.4% in patients treated only with adjuvant but without 
concurrent temozolomide. Given the potential neuro-
toxic impact of the concurrent temozolomide treatment 
to radiotherapy, the pro and contra discussion for concur-
rent temozolomide treatment has to be addressed with 
great caution and more follow-up of the study is clearly 
needed.
Importantly, concurrent and adjuvant temozolomide 
treatment did not improve the survival time the subgroup 
of patients with IDHwt or MGMT unmethylated anaplastic 
astrocytomas.15 However, due to the small sample size in 
the molecular subgroups, conclusions have to be drawn 
with caution, and further molecular analysis is pending.
treatment on progression
Treatment possibilities on progression should be carefully 
considered in an interdisciplinary manner and include 
resurgery, reradiation as well as systemic approaches 
including temozolomide rechallenge and Nitrosourea’s.7 
A randomised study on recurrent 1p/19q intact grade II 
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Figure 2 Illustration of the currently proposed treatment 
schedule in anaplastic astrocytoma without 1p/19q 
codeletion.
and grade III glioma did not observe a benefit in progres-
sion free survival (PFS) or OS of adding bevacizumab to 
temozolomide.18
Further supportive measures
Seizures, cognitive deficits and focal neurological defi-
cits require special attention as they have great impact 
on quality of survival. It is important to realise that over 
time cognitive deficits may progress, and this requires 
ongoing attentiveness for these problems.19 A referral to 
specialised rehabilitation centres will not solve this type of 
problem but may help the patient to better cope with the 
challenges and issues that patients experience in everyday 
life and work. It is at present unclear if combining 
temozolomide with radiotherapy during the radiotherapy 
phase will increase late-onset cognitive deficits in patients 
with a relatively good prognosis compared with treatment 
with radiotherapy alone, but this is a potential concern.
ConClusIons, or: how I treat
In all lesions suspected to present a diffuse glioma, surgery 
should be set up to be as extensive as safely possible. We 
routinely assess grade II and III tumours with next gener-
ation sequencing using a glioma-specific panel including 
IDH, ATRX, H3-K27, 1p/19q, TERT promoter, EGFR as 
well as combined loss of heterozygosity of chromosome 
1p. 19q, 10q and trisomy of chromosome 7. This panel 
allows the assessment of both copy number alterations 
and glioma relevant mutations, and allows the impor-
tant further classification IDHwt and IDHmt anaplastic 
astrocytoma.20 We treat grade II and III tumours with 
‘molecular features of glioblastoma’ as glioblastoma 
with combined chemoirradiation including six cycles 
of adjuvant temozolomide irrespective of the MGMT 
methylation status (figure 2). For anaplastic astrocytoma 
IDHmt, the interim results of the CATNON trials strongly 
suggest treatment with 59.4 Gy radiotherapy in fractions 
of 1.8 Gy followed by 12 cycles of adjuvant temozolomide 
chemotherapy (200 mg/m2 days 1–5 in a 4-week cycle; 
figure 2).7 14 Even in fully resected patients, we continue 
with adjuvant radiotherapy and chemotherapy without 
delay. This proposed regime should be applied in all 
IDHmt patients or in the presence of an MGMT methyl-
ation. In IDHwt patients or in absence of MGMT methyl-
ation, the additional adjuvant treatment with temozolo-
mide should be discussed with a patient. The clinical 
benefit of concomitant temozolomide during radio-
therapy in IDHmt tumors remains to be established until 
the final analysis of the CATNON trails also reporting of 
neuro-cognitive and quality of life based endpoints are 
available.
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